2026年重塑生物制药制造：从研发到产业化的智能跃迁报告（英文版）

Reinventing

biopharma

fromlabtoline

Fuelingsmarter,fasterand

scalablebiopharmaproductionwithintelligenttechnologies

Authors

AnneMariebringsover25yearsofexperienceguidingglobalpharmaceuticalbiotechnology,andmedical

technologycompaniesthroughcomplexoperational

change.AsAccenture’sAmericasLeadforLifeSciencesSupplyChainandOperationsandIndustryXpractice,AnneMarieoverseesadiverseportfolioofclient

engagementsfocusedondigitaltransformation,

operationalresilienceandpatient-centricinnovation.

Herleadershipspansthefullvaluechain,fromstrategy

throughexecution,acrossdomainssuchasintegrated

planning,manufacturingandlogistics.AnneMarieis

akeycontributortoAccenture’sthoughtleadershipin

lifesciences,shapingindustryperspectivesontopics

suchasdigitalmanufacturingtocontractmanufacturingorganizationcollaborationandautonomoussupplychain.

HagenisaManagingDirectorresponsiblefor

Accenture’sIndustryXLifeSciencesofferingin

EMEA.Hehasapproximately25yearsofexperienceinmanufacturing,withaspecificfocusonlarge

biopharmamanufacturingforthepast12years.

Hagenhaslednumeroushigh-profileprojects

forlargebiopharmacompanies,includingIT/OT

partnerships,clinicalstudycontroltowersand

digitaltherapeuticsdevelopment.Hehelpsclients

achieveflexibilityandoperationalexcellencethroughdigitaltransformationinthelifesciencessector.

SelenisAccenture’sResearchLeadforProductsand

LifeSciencesglobally,wheresheoverseesateamof

30+researchers.Sheshapestheindustry’sthought

leadershipagenda,drivinginsightsonscientific

innovation,theconvergenceofscienceandtechnology,andmarketdisruptionsredefiningthefutureofindustries.

Selenbringsdeepexperienceacrossbothstrategy

consultingandresearchleadership.Inhercurrentrole,

shedevelopsCEOperspectivesandcuratesAccenture’s

annualLifeSciencesCEOForum,engagingindustryleaders

onthemostpressingissuesofthefuture.Priortoconsulting,Selenworkedasascientistandprocessdevelopmentengineeratleadingbiopharmaceuticalcompanies,whereshefocused

oncelllinedevelopmentandbioprocessdesign.Basedin

Boston,Massachusetts,shealsoservesontheBiotechnologyIndustrialAdvisoryBoardatNortheasternUniversity.

TheauthorswouldliketothankAmandaRubin,BilalButt,

CamillePlanty,CiaraMcNally,JessicaNagar,JoannaLisiecka,KamilaOchedalska-SzymanskaandKristinaTomes

fortheircontributions

Reinventingbiopharmafromlabtoline

2

Reinventingbiopharmafromlabtoline3

companies

☆

Survey

120manufacturingexperts

80Acrosstopbiopharma

+

Interviews+2ndsurvey

10SeniorExecutives(VP-levelandabove)

Fromtop20

biopharmacompanies

+

Syndicateddataanalysis

Casestudiesandcustomanalyses

FDACompleteResponseLetters(CRLs)–analysis

Whatwedid

20

Mid-sizecompanies/Biosimilarproducers

60-minute

liveinterviews

PipelineModality&R&DAccelerationAnalysis

20

Contractdevelopmentandmanufacturing

organizations(CDMOs)/Contractmanufacturingorganizations(CMOs)

CMCDigitalMaturityBenchmarking

DigitalImpact

CaseStudies

(internal&external)

Abouttheresearch

Scope

Thisreportfocusesonbiopharmaceuticalmanufacturingandsupportingtechnicaloperationsfunctions,includingprocess

development,chemistry,manufacturingandcontrols(CMC)andmanufacturingscienceandtechnology(MS&T).

Throughoutthereportwewilluse

theterms“manufacturing”and

“technicaloperations”interchangeablytorefertothefunctionallandscape.

Theterm“intelligenttechnologies”

isusedtodescribedigitalsolutions

suchasadvanceddataanalytics,AI,

generativeAI,agenticAI,digitaltwins,automationandrobotics.

4

Reinventingbiopharmafromlabtoline

Tableofcontents

06

Biopharmaceuticalmanufacturing

standsatacriticalinflectionpoint

08

Currentstate:Progressamidpersistent

challenges

10

Theroadblocksonthewaytoscale

digitalinitiatives

11

Reinventingtheproductdevelopmentlifecyclewithintelligent

technologies

15

Aroadmapfor

unlockingthe

valueofintelligenttechnologiesin

technicaloperations

32

Futureofbiopharmaproductionis

drivenbyintelligenttechnologies

Executivesummary

Byscalingintelligent

technologiesacrosstheproductlifecycle—fromrobotichigh-

throughputprocessdesign

toAI-augmentedreal-time

analyticsanddecisionmaking—biopharmaleaderscanreduce

costs,acceleratelaunchesandbuildmorereliable,adaptivemanufacturingsystems.

Reinventingbiopharmafromlabtoline5

Manufacturingisnowonthecriticalpathtodeliveringessentialmedicinestopatients,apivotalmomentthatdemandstighterintegrationfromlabtolinetoensurespeed,reliability,andquality.Complexbiologics

pipelines,AI-acceleratedR&Dandmounting

geopoliticalandeconomicpressureshavecatapultedmanufacturingtoatoppriority,andwithgoodreason—

64%ofdrug-launchdelaysin2024stemmedfromchemistry,manufacturingandcontrolissues.1

Anewgenerationofintegrateddigitalecosystems,

poweredbyadvancedanalytics,AI,digitaltwins,

intelligentagentsandrobotics,promisetotransformbiopharmamanufacturingandprocessdevelopment.Organizationsthatlaytherightdataandinfrastructurefoundationsarerealizingcompetitiveadvantage

includingfastertime-to-marketinacrowdedtherapeuticlandscape,lowerproductioncoststhroughsmarter,moreefficientprocessesandareliable,uninterruptedsupplythatsafeguardspatientaccess.

Although28%ofourglobalsurveyrespondentsfromtopbiopharmacompaniesalreadyhaveaccessto

advancedintelligenttools—supportingpredictiveorevenpartiallyautonomousprocesses—mostcompaniesarestillintheearlystagesofscalingthesecapabilities

withdigitalinnovationconfinedtoisolatedinitiatives.Evenamongcompaniesachievinghighdigital

maturitylevels,certainteamsoperatewithadvancedcapabilitieswhileothersstilldependonlegacytoolsandmanualworkflows.Withsomanyleversyettobepulled,thereissignificantuntappedvalueinmore

broadlyembeddingintelligenttechnologiesacrosstechnicaloperations.

Whatshouldbiopharmacompaniesdotorealize

thefullpotentialofintelligenttechnologies?

Buildingonourexperiencedeliveringover2,000

projectsacrossindustries,thisresearchprovides

apragmaticplaybookforsuccess,anchoredinthreekeyfocusareas:Leadwithvalue,buildasoliddata-and-systemsfoundationandreinventworkflowsand

waysofworking.

Data,AIandotherintelligenttechnologiesarealreadyrewritingtherulesacrosstheindustry.Asthese

capabilitiesadvance,manufacturinghasthepotentialtobecomeapowerfulenginefortransformation

ratherthanalimitingfactor.Leaderswhoact

now,withpurposeandcoherence,cantransformmanufacturingintoacatalystforenterprise-wideinnovationandsustainedcompetitiveadvantage.

6

Reinventingbiopharmafromlabtoline

Biopharmaceuticalmanufacturing

standsatacriticalinflectionpoint

Asthecomplexityofmodalitiesindrugpipelines

increasesandAI-acceleratedR&Dcompresses

developmenttimelines,manufacturinghassteppedintothespotlight.Onceabehind-the-scenesfunction,itnowholdsthepotentialtobecomeastrategic

differentiator,asourceofcompetitiveadvantage.Ontheflipside,manufacturingcouldbecome

abottleneckinbringingtherapiestomarketifneglected.

Thepressureonmanufacturingandtechnicaloperationscontinuestomount,drivenbythreepowerfulforces:

Increasingmolecularcomplexity,withbiologicsnowrepresenting55%ofclinicalpipelines.2

AI-drivenaccelerationofdrugdiscoveryandclinicaltrials,whichdemandsthatprocess

developmentandmanufacturingkeeppace.

Broaderexternalchallenges,includinggeopoliticalandeconomicvolatility,supplychaindisruptions,andintensifyingcompetition.

Thesedynamicsarereshapingwhatittakesto

succeedinmanufacturing.Teamsmustmaketheiroperationsmoreresilient,scalableandadaptable—allwhilemanagingrisingcostsofgoodssoldandgrowinguncertainty.

Theurgencyforchangeisclear.Ouranalysisof

FDACompleteResponseLetters(CRLs)issuedto

toppharmaceuticalcompaniesbetween2009

and2024showsthatlastyearwasunprecedented:

overhalf(64%)ofmarketdelayswereduetochemistry,manufacturingandcontrols(CMC)issues,delayingbothpatientaccessandrevenues.3Mostofthese

setbacksstemmedfromtheproductionofcomplexbiologics,underscoringthestrainontoday’s

technicaloperationsfunctions.

Wewon'tbeabletooptimizethecostofgoodsunlesswedigitalize.

Sosuddenly,thisbecomesR&D’sproblemandcommercial’sproblemtoo—andthat’stheopportunityformanufacturingandCMCtostepinandlead.”

HeadofDigital&AITransformation

Top20largebiopharmacompany

Reinventingbiopharmafromlabtoline7

Thekeytobuildingresiliencetopotentialdisruptionsimpactingpharmaceuticalmanufacturingliesin

harnessingthepowerofdataandintelligenttechnologies.Inanerawheredataitselfisastrategicasset,improvingdataconnectivityandapplyingadvancedanalytics,AI,processtwins,roboticsandAIagentscandramaticallyboostspeedandefficiency.Thesetechnologiescanalsoreducecostsandstrengthenpreparednessforcurrentandfuturechallenges.Thenextfrontierbelongstothosewhocanleverage

intelligenttechnologytoaugment—andevenautomate—criticalworkflows,enablingworkerstoworkalongsideintelligentsystems.

Forexecutives,thestakescouldnotbehigher.Ourresearchfoundthatcompaniesmodernizingtheirmanufacturingoperationsstandtocapturethreecriticaladvantages:

•Acceleratedtime-to-marketinanincreasinglycompetitivelandscape.

•Significantlylowerproductioncosts.4

•Secureanuninterruptedsupplyofmedicinestopatients.

Thecurrentstate:Progressamidpersistentchallenges

Ourresearchindicatesthatthepharmaceuticalsectorisatapivotaljunctureinitsdigitaltransformationjourney.Anewwaveofadvancedanalyticsand

AIisrapidlyemerging,yetadoptionvariessignificantlyacrossorganizations.

Inourglobalsurvey,5asignificantportionoftopbiopharmaorganizations

remain“stuckinthemiddle”oftheirdigitaljourney.35%ofsurveyedexecutivesindicatedtheircompaniesfunctionas“connectedorganizations.”Ourfollow-upinterviewsrevealedthatevenamongthoseachievinghighlevelsofadvanced

intelligenttechnologiesadoption,significantdisparitiespersistacrossbusinessunits,modalitiesandsites.19%oftopbiopharmaexecutivesreportedoperatingina“predictive”environment.6Thismeanstheyareleveragingintegrated

systemsthatcombinehistoricalandreal-timedatawithAImodelstoenable

proactiveprocessoptimization,enhanceoperationalefficiencyandsupport

data-drivendecision-making.Lessthan10%ofrespondentsreportedoperatinginan“adaptive”environment,havingpartiallyautonomous,self-optimizing

processespoweredbyAI,machinelearning(ML)androbotics.

Reinventingbiopharmafromlabtoline

Thevaluedeliveredbyintelligentsolutions,evenforthosein"connectedorganizations"stageisnolongerhypothetical.Companiesarereportingmeasurableimpactacrosskeyareasoftechnicaloperations(seeFigure1).

Figure1:

Largebiopharmacompaniesareseeingmeasurablegainsacrosskeytechnicaloperationsareas

01

02

03

04

05

Increasedefficiencyday-to-daysupply

Improved

techtransfer

Expedited

developmentofrecipes

Expedited

regulatoryfilings

Improvedmaterialtraceability

54%

Increasedefficiencyinday-to-daysupplyasenhancedfactory,labandnetworkoperationshaveimprovedmaterialavailability,

qualitychecks,andprocesscontrol,bothwithinandacrosssites.

45%

ImprovedtechtransferviastreamlineddataandknowledgesharingacrossR&D,manufacturingandqualityteams,

acceleratingclinicalandcommercialsupplyatscale.

38%

Expediteddevelopmentofrecipesviareduced

numberofdesignofexperiment(DoE)runsleadingtohigher-yieldformulationsinlesstime.

34%

Expeditedregulatoryfilingswithminimalmanualeffort,reducingadministrative

burdenandimprovingapprovaltimelines.

31%

Improvedmaterialtraceabilityviagreatervisibility

intomaterialhistoryallthewaybacktoprimaryand

secondarysuppliersthroughtheirCMOsandCDMOs.

Source:AccentureResearchSurvey2025;Toppharmacompanies(n=80)

8

“We’vebeensystematicallyimprovingthepredictivecapabilitiesofthese

tools.Lastyear,wehadthefastesttechtransferever—ofanassetthatcamethroughanacquisition.

Wehadverylittlepriorknowledge,butwewereabletode-riskthe

techtransferandimproveprocessperformance,allofit"insilico."

HeadofDigital&AITransformation

Top20biopharmacompany

Reinventingbiopharmafromlabtoline

Increasedefficiencyinday-to-daysupply

Amajorityoftopbiopharmaexecutives(54%)

reportedimprovementsinday-to-daysupply

efficiency,translatingintofastertime-to-market

andleanercoststructures.Anadvancedexample,sharedbyanexecutivefromaleadingglobal

biopharmacompany,involvedembeddingAIandreal-timeanalyticsintoitsmanufacturingoperations.Thisapproachwasusedtoaddressvariabilityintheirkeybiologicproduct.Bycontinuouslyanalyzing

thousandsofreal-timeprocessvariablesusing

machinelearning,thesystemidentified10–15keypredictorsthatmoststronglyinfluencedyield.

Thisenabledoperatorstointerveneproactively—withinvalidatedranges—beforedeviationscouldimpactoutcomes.

Asaresult,thecompanyhascreatedasmarter,moreadaptiveproductionenvironmentthat

ensureshigherefficiencyandproductquality,

reducingwasteinmanufacturing.AllofthiswaspossiblebecauseofembeddingAIdirectlyintolivemanufacturingoperations.

Improvedtechtransfer

Similarly,45%ofexecutiveshighlightedmajoradvancementsintechnologytransfer.

Onecompanyimplementedcomputer-based

simulationmodeling(knownasinsilicomodeling)topredictoptimalmanufacturingparameters

priortophysicalexecution.Thisapproachprovedespeciallyvaluableduringthetransferofan

acquiredassetwithlimitedpriordocumentation.Asaresult,theyachievedtheirfastesttech

9

transferofanassetthroughacquisitiontodate.

Theroadblocksonthewaytoscaledigitalinitiatives

Whiletherearegreatsuccessstories,mostcompaniestodaystandat

aninflectionpoint(seeFigure2).Thosethatsucceedinindustrializing

theirdigitalcapabilitieshavetheopportunitytoscalerapidlyandprogresstowardfullyautonomous,end-to-endoperations.7

Yet,thispotentialremainslargelyuntapped.Ourresearchrevealsthreepersistentbarriersholdingbackprogress:

•Digitalpilotsareoftenconfinedtolow-risk,low-impactareas.

•Coredatainfrastructureandsystemsarenotyetreadytosupportscale.

•Initiativesremainsiloedwithinfunctions,eg.productdevelopment,MS&T,regulatoryandqualityandIT/digital.

Theresult?Fragmentedsolutionswithlimitedreturnoninvestment(ROI),digitalinitiativesthatcannotscaleandagrowingnumberof“digitaldeadends”.8Thesedisconnectsarewideningthegapbetweenambitionand

execution.Ifleftunaddressed,theindustry’sdigitalmomentumcouldstall,orworserequirecostlyrework.

Reinventingbiopharmafromlabtoline

Whilethesehurdleshavestalledprogress,theyalsorevealaclearopportunitytorethinktheroleofintelligenttechnologiesandunlockimprovementsacrosstheentireproductdevelopmentlifecycle.

Value

Figure2:

Crossingtheinflectionpointfromexperimentationtoexecutioncallsforreinvention

Industrialize

Hyper-scaling

End-to-endautonomousoperations

Globalstandards,bestpractice

sharing

Toppharmacompanies

arehere

LocalsolutionswithlimitedROI

Nostandards

tohyper-scale

Digital

deadends

Inflectionpoint

(Readinesstoindustrialize)

MVP*

PilotExplore

Maturity

*MVP-minimumviableproduct

Source:Accentureanalysis

10

11

Reinventingbiopharmafromlabtoline

Reinventingtheproduct

developmentlifecyclewithintelligenttechnologies

Reinventingtheproductdevelopmentlifecycledemandsabold,clearvision.Toallocatehumancapitalandspendwisely,technicaloperations

leadersshouldwork“fromthefutureback,”

firstconceptualizinganddesigningtheoptimalAI-enabledtechnologystacksupportingatruedigitalthreadandthenasking,“Whatdoesgoodlooklike—andhowdowegettheretogether?”

Envisionanend-to-end,AI-poweredplatformthatreshapeseverystageoftheproduct

lifecycle.Forthepurposeofthisreport,

we'lluseanantibody-drugconjugates(ADCs)asaproxyforanadvancedmodalitythatcan

progressthroughtheproductlifecycleatpace.AIormachinelearningtoolscanaccelerate

thisprocessbyidentifyingoptimaltargetsandoptimizingantibodysequences.9

This,coupledwithpredictingthebestlinker-payloadcombinationsandsimulatingefficacyandtoxicityprofilescansignificantlyreduceearly-stagedevelopmenttimeline.10

Asgroundbreakingasitis,AI-accelerateddrugdesignalsoputstechnicaloperationsunder

growingpressure,requiringthecreationofanequallyfastdevelopmentprocess.

Tofullycapturetheeconomicbenefitsof

acceleratedR&D,companiesmustoptimizethe

entireproductlifecycle,fromproductdevelopmentlabstoproductionlines—andintelligenttechnologiescanplayapivotalroleacrosseveryfunctionateverystageoftechnicaloperations(seeTable1).Withtherightdigitalcapabilitiesinplace,organizations

cansignificantlyshortentimelinesfrominitialcandidatetoapproval.

12

Reinventingbiopharmafromlabtoline

Table1:

Howtoleverageintelligenttechnologiesacrossfunctionstoimprovetheproductlifecycle[illustrativeexamples,notexhaustive]

Stage

Intelligenttechnologies

Outcomes

Process

Development

AI/ML-enabledprocessmodeling(robotichigh-throughputDoE)11

Digitaltwinprocesssimulation(virtualprocessreplica)12

Reducelabwork,acceleratedevelopment(e.g.,fasteridentificationofoptimalcelllines,conjugationconditionsandoptimalprocessparameters)andimproveyield

Consistencyandscalabilitywhilereducingprocessdevelopmenttime

Analytical

Methods

Processanalyticaltechnology(PAT)andreal-timemonitoring

Ensureconsistencyandscalabilityandreducebatchreleasetimes,improvesupplychainpredictability

Techtransfer/Scaleup

AI-poweredenterpriseknowledgemanagementtools

Digitalproductlifecyclemanagement(PLM)systemwithdynamicprocessflowdescriptions

Predictprocessvariations,mitigaterisksandensureseamlesstransitionsfromearly-stageproductiontocommercial-scalemanufacturing

Eliminatestaticdocumentinefficiencies,reduceerrorsinknowledgetransfer

Regulatorysubmissions

GenerativeAI-powereddocumentationautomation

AccelerateCMCdossiercompilation,submissionsandresponsestoregulatoryqueries

Post-launch

Continuedprocessverification(CPV)analyticsusing

Maintainconsistentproductqualityovertimeandregulatorycompliance

AI/advancedanalytics

bydocumentingstableoperationsandfastcorrectiveactions

13

Reinventingbiopharmafromlabtoline

Ourexperience,researchandindustrycasestudiesshowclearquantifiablebenefitsofadoptingintelligenttechnologiesintheproductdevelopmentlifecycle:

•Reducedtime-to-marketbyupto40%13

•Improvedthroughputinprocessdevelopmentby30%14

•Yieldenhancementsofover400%inupstream(cellculture)processes,withfurthercumulativegainspossibleacrossdownstreamandconjugationsteps,loweringcosts,carbonfootprintandfuturecapacityneeds15

•Batchleadtimereductionofupto50%,minimizingwork-in-progressinventory16

•Increasedefficiencyindeviationinvestigations,cuttinganalysistimebyover50%17

AsseeninFigure3,adoptionofintelligenttechnologiesacrosstheproductlifecyclecanunlockunprecedentedvalueforbiopharmacompanies.

Reinventingbiopharmafromlabtoline14

Figure3:

Fromgoodtogreat:reinventingtheproductlifecycle

Typicalproductlifecycle

●Enhancedproductlifecycle

LeadOp.&Ph1Ph2Ph3LaunchGrowthMaturityDeclinePatentExpirationand/or

Pre-Clinical

Acceleratedevelopment&launch

•AccelerateCMCprocess

•Fastertechtransfer

•Fasterregulatoryapprovalacrossmultiplemarkets

MaximizesalesandminimizeCOGS

•Higheryieldsandefficiency

•Highersalesthroughfasterlaunchof

1st,2nd,3rdgenerationprocesses

•Greater‘rightfirsttime’resultinginfewerdeviations

Launch

Launch

DiscoveryClinicalSupplyCommercialSupply

GenericCompetition

Optimizesupplychainandcustomerservice

•Reducewasteandincreaseefficiency

•Improvedontimeinfull(OTIF)dueto

improvedmanufacturingprocesscapability

Revenue

Time

Byfollowingthistransformationblueprint,biopharmacompaniescan:

01Acceleratedrugdevelopment

andlaunchbyacceleratingall

underlyingactivitieslikeCMC

processdevelopment,techtransferandregulatorysubmissionsacrossmultiplemarkets.

02Maximizesalesandmargins

withhigheryieldandefficiency,

fewerdeviationsandfasterlaunchesofrightfirst-timeprocesses.

03Optimizesupplychainandincrease

customersatisfactionbyreducing

waste,improvingon-timein-full

(OTIF)duetoimprovedmanufacturingandreducingissueresolutiontime.

15

Reinventingbiopharmafromlabtoline

Aroadmapforunlocking

thevalueofintelligenttechnologiesintechnicaloperations

Drawingoninsightsfrommorethan2,000projectsimplementingintelligenttechnologiesacrossindustries,18weprovideaclearandpracticalguideforexecutingsuccessfuldigital

CMCtransformationprograms.Theserecommendationsaregroundedinfindingsfromour

globalsurveyof120technicaloperationsexpertsandin-depthinterviewswithseniorexecutives,offeringaviewintohowdigitaltransformationplaysoutinreal-worldCMCenvironments.

Theinsightsareorganizedaroundthreekeyfocusareasthattogetherdefinewhatittakestoscaleintelligenttechnologieseffectivelyinmanufacturingandtechnicaloperations.

01

Leadwithvalue

Anchoreveryinitiativein

aquantified

businesscase

02

Buildasolid

data-and-systemsfoundation

Standardizedata,

integrateplatformsandautomateflows

03

Reinvent

workflowsand

waysofworking

Redesignrolesand

processestoexploitthenewdigitalcapabilities

16

Reinventingbiopharmafromlabtoline

Focusarea01

Leadwithvalue

TherecentMITNANDAStateofAIinBusiness2025reportwarnsthat95%oforganizationsareseeingnoreturnsfromtheirgenerative

AIinvestments.

Thefewthatachieveresultsfocusontailoring

solutionstospecificprocessesandassessing

toolsthroughthelensofmeasurablebusiness

outcomes.19AsharperfocusonROI—andon

thepotentialvaluelostbynotacting—isessential.

Usingintelligenttechnologiestosystematically

accelerateinnovation,enhanceoperational

capabilitiesandfuellong-termgrowthrequires

anewmindset:onethatmovesbeyondisolated

proofsofconceptandinsteadreimagineshow

coreprocessesandsystemscanbefundamentallytransformed.Organizationsthatadoptthisvalue-firstapproacharebestpositionedtounlock

thefullpromiseofdigitalreinvention.

Leadwithvalue

Action01

Harnessthe

powerofintelligenttechnologiesin

technicaloperationswithaboldend-to-

endvision

Focusarea01

Reinventingbiopharmafromlabtoline17

Avisionwhereintelligenttechnologiessupport

theproductdeliveryend-to-end(fromlabtoline)isessentialtoestablishfullyrobustandresilientbiopharmaproductionprocesses.Withstrong

leadershipcommitment,technicaloperations

canbecomepowerfulgrowthdrivers—enablingfasterdecisions,strongerportfoliodeliveryandalastingcompetitiveedge.

“Webegandiscussingdigital

transformationintermsof

additionalmoleculesandnewopportunities.Ifwecould

implement[specificdigital

capabilities]wecouldtake

ontwomoremoleculesayearwithoutincreasingheadcount.”

HeadofDigital&AITransformation,ProcessDevelopment

Top20biopharmacompany

Leadwithvalue

Action02

Bevalue-ledineverybusinesscapabilityyoureinvent

Focusarea01

Reinventingbiopharmafromlabtoline